Mirabegron Stada (Mirabegron)

Mirabegron selectively activates β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation raises cyclic AMP levels, causing the muscle to relax during the storage phase, which expands bladder capacity and reduces involuntary contractions that trigger urgency and leakage.

The appropriate dose of Mirabegron Stada is determined by the prescribing healthcare professional based on the patient’s medical condition, renal function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Mirabegron Stada in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike anticholinergics, which block muscarinic receptors and may cause dry mouth or constipation, Mirabegron works by stimulating β3‑adrenergic receptors, offering an alternative mechanism with a different side‑effect profile. Choice of therapy depends on patient tolerance, comorbidities and physician judgment.

Mirabegron Stada should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in bathrooms or near heat sources, and keep the container tightly closed when not in use.

Mirabegron Stada is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include significant hypertension, urinary retention that may require catheterisation, and rare cases of angle‑closure glaucoma. Patients should be educated to report sudden increases in blood pressure, difficulty emptying the bladder, or eye pain promptly.

Mirabegron Stada is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any excipients. It should also be avoided in individuals taking strong CYP2D6 or CYP3A4 inhibitors without appropriate medical supervision.